EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross‐Sectional Study in Israel

Lior Tsviban iD, Nofar Amitai iD, Hagit Levine iD, Eyal Jacobi iD, Einat Shmueli iD, Miri Dotan iD, Huda Mussaffi iD, Hannah Blau, Patrick Stafler iD, Meir Mei-Zahav iD, Aielet Stolovas, Malena Cohen-Cymberknoh iD und 10 weitere

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71343 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Lior Tsviban und 21 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Institute and Graub CF Center, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Cystic Fibrosis, Vaccination Coverage, Vaccination. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vaccines are a cornerstone of modern medicine, however, in some regions, low coverage is reported in patients with chronic diseases, including people with cystic fibrosis (pwCF), compared to the general population.

Methods

This retrospective multicenter study in Israel included pwCF born after January 1, 2000, and compared them to the general population. Vaccination data were collected from patient databases and the Ministry of Health reports for the general population.

Results

Out of 269 eligible pwCF aged 6 months to 23 years, a total of 173 were included. Coverage for the initial DTaP‐IPV‐HiB vaccine, administered in the first year of life, was similar between pwCF and the general population (92% compared with 96%, p = 0.23). In contrast, coverage for other routine vaccines given in the first year of life was significantly lower in pwCF: HAV (76% compared with 92%), HBV (85% compared with 96%), and the first dose of MMRV (85% compared with 97%) (all p < 0.001). Booster dose coverage for DTaP‐IPV‐HiB and MMRV, given at age 6–7 years, was also significantly reduced in pwCF (72% compared with 95% and 68% compared with 96% respectively, p < 0.001). Pneumococcal conjugate vaccine uptake was significantly lower in pwCF (61.8% vs. 94% in the general population p < 0.001), while the 23‐valent pneumococcal vaccine was slightly more prevalent among pwCF compared to those with other chronic conditions, although uptake was low in both groups (15% vs. 10%, p = 0.001). Influenza vaccination rates during 3 seasons were significantly higher in pwCF (65%–70% vs. 20‐27% in the general population, p < 0.001), whereas COVID‐19 vaccine uptake was lower in adolescent pwCF compared to their general population peers (38.5% vs. 57.4%, p = 0.04).

Conclusion

Our study highlights suboptimal vaccine coverage among pwCF, particularly after the first year of life, affecting both routine early‐life vaccines and booster doses. Greater awareness and proactive measures are needed to ensure adequate vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisVaccination CoverageVaccinationHumansIsraelChildRetrospective StudiesAdolescentCross-Sectional StudiesMaleChild, PreschoolFemaleInfantYoung AdultPneumococcal Vaccines

Stichwörter der Autor:innen

booster vaccinescystic fibrosisroutine vaccinesvaccine coverage

Substanzen

Pneumococcal Vaccines

Autor:innen und Institutionen

  • Pulmonary Institute and Graub CF Center, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • School of Medicine, Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
  • Pediatric Pulmonary Unit and Cystic Fibrosis Center, Hadassah Medical Center, Jerusalem, Israel.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Pediatric Pulmonary Institute and CF Center, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
  • Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

ORCID-Profile: Lior Tsviban, Nofar Amitai, Hagit Levine, Eyal Jacobi, Einat Shmueli, Miri Dotan, Huda Mussaffi, Patrick Stafler, Meir Mei-Zahav, Malena Cohen-Cymberknoh, Michal Gur, Ronen Bar-Yoseph, Karin Yaacoby-Bianu, Noga Arwas, Inbal Golan-Tripto, Dario Prais, Ophir Bar-On

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Tsviban, L., Amitai, N., Levine, H., Jacobi, E., Shmueli, E., Dotan, M., Mussaffi, H., Blau, H., Stafler, P., Mei-Zahav, M., Stolovas, A., Cohen-Cymberknoh, M., Gur, M., Bar-Yoseph, R., Yaacoby-Bianu, K., Ostrovsky, A., Livnat, G., Arwas, N., Golan-Tripto, I., …, & Bar-On, O. (2025). Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross‐Sectional Study in Israel. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71343

Vancouver

Tsviban L, Amitai N, Levine H, Jacobi E, Shmueli E, Dotan M, et al. Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross‐Sectional Study in Israel. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71343

BibTeX
@article{Tsviban2025,
  author = {Tsviban, Lior and Amitai, Nofar and Levine, Hagit and Jacobi, Eyal and Shmueli, Einat and Dotan, Miri and Mussaffi, Huda and Blau, Hannah and Stafler, Patrick and Mei-Zahav, Meir and Stolovas, Aielet and Cohen-Cymberknoh, Malena and Gur, Michal and Bar-Yoseph, Ronen and Yaacoby-Bianu, Karin and Ostrovsky, Anna and Livnat, Galit and Arwas, Noga and Golan-Tripto, Inbal and Dagan, Adi and Prais, Dario and Bar-On, Ophir},
  title = {Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross‐Sectional Study in Israel},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71343}
}
Kostenlos starten →